Physician profile
Adelaide Smith
NPI 1174927370
$5,355.85
in general payments reported to CMS, 2019-2025
23 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $695 · 2023: $1,486 · 2024: $1,230 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,262 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,262.00 |
| Education | $292.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.06 | 2021-2025 | |
| Janssen Biotech, INC. | $815.84 | 2022-2025 | Tremfya |
| Incyte Corporation | $621.16 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $489.53 | 2023-2025 | Sotyktu |
| Amgen INC. | $256.75 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $250.39 | 2022-2025 | |
| Lilly USA, LLC | $248.25 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $248.16 | 2022-2025 | Ilumya |
| Dermavant Sciences, INC. | $199.07 | 2023-2024 | Vtama |
| Botanix Sb INC | $176.40 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.15 | 2024-2025 | Cabtreo, Siliq, Arazlo |
| Journey Medical Corporation | $124.94 | 2023-2025 | |
| Ucb, INC. | $114.55 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $90.13 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $64.71 | 2023-2025 | Nemluvio, Aklief |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $58.27 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $56.28 | 2024-2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $38.38 | 2024-2025 | Ycanth |
| Mayne Pharma Commercial LLC | $37.68 | 2022 | |
| Pfizer INC. | $35.02 | 2023 | |
| Sonendo INC | $34.78 | 2023 | Posterior Cleanflow Procedure Instrument With Matrices |
| Organon LLC | $22.60 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.75 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelaide Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.